Theriva Biologics Inc (TOVX) FinancialsTOVXFinancialTheriva Biologics Inc

Evaluating the bottom line, Theriva Biologics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -709.00%, while the net margin is -681.33%. These profitability ratios, combined with a Return on Equity (ROE) of -148.69%, provide a clear picture of how effectively TOVX converts its operational activities into shareholder value.

In the context of the broader market, TOVX competes directly with industry leaders such as KPRX and AZTR. With a market capitalization of $10.46M, it holds a significant position in the sector. When comparing efficiency, TOVX's gross margin of 100.00% stands against KPRX's N/A and AZTR's N/A. Such benchmarking helps identify whether Theriva Biologics Inc is trading at a premium or discount relative to its financial performance.

Theriva Biologics has shown a significant improvement in its financial performance, with a gross margin of 100% in Q1 2026, indicating potential for profitability as revenues grow. The net income loss has narrowed significantly, from $4.32 million to $2.04 million year-over-year, suggesting better cost management.